Publications by authors named "Uta Oelschlaegel"

Claim this Profile
H
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Katja Sockel, Christoph Röllig, Anke Mütherig, Martina Crysandt, Sven Zukunft, Uta Oelschlaegel

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Anne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, Katja Sockel, Rebekka Wehner, Uta Oelschlaegel

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia.
Karin D Prummel, Kevin Woods, Maksim Kholmatov, Eric C Schmitt, Evi P Vlachou, Uta Oelschlaegel

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML.
Uta Oelschlaegel, Jonas Schadt, Katharina Epp, Lisa Wagenführ, Leo Ruhnke

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory Mesenchymal Stromal Cells and IFN-responsive T cells are key mediators of human bone marrow niche remodeling in CHIP and MDS.
Karin D Prummel, Kevin Woods, Maksim Kholmatov, Eric C Schmitt, Evi P Vlachou, Uta Oelschlaegel

bioRxiv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR monocytes in lower-risk myelodysplastic neoplasms.
Susann Winter, Marie Schneider, Uta Oelschlaegel, Giulia Maggioni, Elena Riva

Leukemia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Cristina A Tentori, Lin P Zhao, Benedetta Tinterri, Kathryn E Strange, Katharina Zoldan, Uta Oelschlaegel

Hemasphere· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDS-PB13 Score - Blood based detection of aberrancies by flow cytometry in patients with suspected and confirmed Myelodysplastic Neoplasms.
Uta Oelschlaegel, Susann Winter, Katja Sockel, Katharina Epp, Jonas Schadt

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact.
Uta Oelschlaegel, Lorenz Oelschlaeger, Malte von Bonin, Michael Kramer, Katja Sockel

Cytometry B Clin Cytom· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.
Vincent H J van der Velden, Frank Preijers, Ulrika Johansson, Theresia M Westers, Alan Dunlop, Uta Oelschlaegel

Cytometry B Clin Cytom· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.
Arjan A van de Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Uta Oelschlaegel

Cytometry B Clin Cytom· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.
Wolfgang Kern, Theresia M Westers, Frauke Bellos, Marie Christine Bene, Peter Bettelheim, Uta Oelschlaegel

Cytometry B Clin Cytom· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.
Anna Porwit, Marie C Béné, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel

Cytometry B Clin Cytom· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.
Sebastian Stasik, Clara Burkhard-Meier, Michael Kramer, Jan M Middeke, Uta Oelschlaegel

Blood Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
Kristina Hölig, Helmuth Schmidt, Gero Hütter, Michael Kramer, Raphael Teipel, Uta Oelschlaegel

Bone Marrow Transplant· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome.
Dolores Subirá, Canan Alhan, Uta Oelschlaegel, Anna Porwit, Katherina Psarra

Ann Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.
Kristina Hölig, Helmuth Schmidt, Gero Hütter, Michael Kramer, Raphael Teipel, Uta Oelschlaegel

Bone Marrow Transplant· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Silvan Francke, Anna Mies, Manja Meggendorfer, Uta Oelschlaegel, Ekaterina Balaian

Leuk Lymphoma· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.
Theresia M Westers, Eline M P Cremers, Uta Oelschlaegel, Ulrika Johansson, Peter Bettelheim

Haematologica· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Ekaterina Balaian, Claudia Schuster, Claudia Schönefeldt, Ulrich Germing, Detlef Haase, Uta Oelschlaegel

Ann Hematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
Uta Oelschlaegel, Theresia M Westers, Brigitte Mohr, Michael Kramer, Stefani Parmentier

Haematologica· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment to the response to "severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome".
Uta Oelschlaegel, Stefani Parmentier, Uwe Platzbecker

Ann Hematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
Arjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, Matteo G Della Porta, Canan Alhan, Uta Oelschlaegel

Leuk Lymphoma· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome.
Stefani Parmentier, Joern Meinel, Uta Oelschlaegel, Brigitte Mohr, Gerhard Ehninger

Ann Hematol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
Markus Schaich, Christoph Röllig, Silke Soucek, Michael Kramer, Christian Thiede, Uta Oelschlaegel

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis